QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF

摘要

4-Amino-6-(4-amino-1-oxo-but-2-enylamino)-quinazoline derivatives (I) are new. 4-Amino-6-(4-amino-1-oxo-but-2-enylamino)-quinazoline derivatives of formula (I) and their tautomers, stereoisomers and salts are new. [Image] R abenzyl, 1-phenylethyl or 3-chloro-4-fluorophenyl; R bdimethylamino, N-methyl-N-ethylamino, Diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)-amino, N-ethyl-N-(2-methoxyethyl)-amino, bis-(2-methoxyethyl)-amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)-amino, N-methyl-N-(tetrahydrofuran-2-yl-methyl)-amino, N-methyl-N-(tetrahydrofuran-3-yl-methyl)-amino, N-methyl-N-(tetrahydropyran-4-yl)-amino or N-methyl-N-(tetrahydropyran-4-ylmethyl)-amino; R ccyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-yl-methoxy, tetrahydrofuran-3-yl-methoxy, tetrahydropyran-4-yloxy or tetrahydropyran-4-ylmethoxy; and provided the following compounds are excluded: (1) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(N,N-diethylamino)-1-oxo-2-buten-1-yl)-amino)-7-cyclopropylmethoxy-quinazoline; (2) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(morpholin-4-yl)-1-oxo-2-buten-1-yl)-amino)-7-cyclopropylmethoxy-quinazoline; (3) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(dimethylamino)-1-oxo-2-buten-1-yl)-amino)-7-cyclopropylmethoxy-quinazoline; (4) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(morpholin-4-yl)-1-oxo-2-buten-1-yl)-amino)-7-cyclobutyloxy-quinazoline; (5) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(morpholin-4-yl)-1-oxo-2-buten-1-yl)-amino)-7-cyclopentyloxy-quinazoline; (6) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(diethylamino)-1-oxo-2-buten-1-yl)-amino)-7-cyclobutyloxy-quinazoline; (7) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(diethylamino)-1-oxo-2-buten-1-yl)-amino)-7-cyclopentyloxy-quinazoline; (8) 4-((R)-(1-phenyl-ethyl)-amino)-6-((4-(morpholin-4-yl)-1-oxo-2-buten-1-yl)-amino)-7-cyclobutyloxy-quinazoline; (9) 4-((R)-(1-phenyl-ethyl)-amino)-6-((4-(morpholin-4-yl)-1-oxo-2-buten-1-yl)-amino)-7-cyclopropylmethoxy-quinazoline; (10) 4-((R)-(1-phenyl-ethyl)-amino)-6-((4-(morpholin-4-yl)-1-oxo-2-buten-1-yl)-amino)-7-cyclopentyloxy-quinazoline; (11) 4-((R)-(1-phenyl-ethyl)-amino)-6-((4-(diethylamino)-1-oxo-2-buten-1-yl)-amino)-7-cyclobutyloxy-quinazoline; (12) 4-((R)-(1-phenyl-ethyl)-amino)-6-((4-(diethylamino)-1-oxo-2-buten-1-yl)-amino)-7-cyclopentyloxy-quinazoline; (13) 4-((R)-(1-phenyl-ethyl)-amino)-6-((4-(diethylamino)-1-oxo-2-buten-1-yl)-amino)-7-cyclopropylmethoxy-quinazoline; (14) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(bis-(2-methoxyethyl)-amino)-1-oxo-2-buten-1-yl)-amino)-7-cyclopropylmethoxy-quinazoline; (15) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(N-ethyl-N-(2-methoxyethyl)-amino)-1-oxo-2-buten-1-yl)-amino)-7-cyclopropylmethoxy-quinazoline; (16) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(N-methyl-N-(tetrahydropyran-4-yl)-amino)-1-oxo-2-buten-1-yl)-amino)-7-cyclopropylmethoxy-quinazoline; (17) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(diethylamino)-1-oxo-2-buten-1-yl)-amino)-7-(tetrahydrofuran-2-yl)-methoxy)-quinazoline; (18) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(diethylamino)-1-oxo-2-buten-1-yl)-amino)-7-(tetrahydrofuran-3-yl)-oxy)-quinazoline; (19) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(diethylamino)-1-oxo-2-buten-1-yl)-amino)-7-(tetrahydropyran-4-yl)-oxy)-quinazoline; (20) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(N-methyl-N-(tetrahydrofuran-2-yl-methyl)-amino)-1-oxo-2-buten-1-yl)-amino)-7-cyclopropylmethoxy-quinazoline; and (21) 4-((3-chloro-4-fluorophenyl)-amino)-6-((4-(N-methyl-N-(tetrahydrofuran-3-yl)-amino)-1-oxo-2-buten-1-yl)-amino)-7-cyclopropylmethoxy-quinazoline. An independent claim is included for the preparation of (I). ACTIVITY : Cytostatic; Respiratory; Gastrointestinal; Antiinflammatory; Antiasthmatic; Antiallergic; Antitussive; Antiulcer; Immunosuppressive; Antipsoriatic. MECHANISM OF ACTION : Tyrosine kinase-mediated signal transduction inhibitor. In a test, 4-((3-Chloro-4-fluorophenyl)-amino)-6-((4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)-amino)-7-((S)-(tetrahydrofuran-2-yl)-methoxy)-quinazoline (Ia) had IC 5 0 value 0.3 MicroM for inhibition of human EGF-receptor kinase.